Altogether, these findings suggest that chemoresistant tumours can be successfully sensitized to conventional chemotherapy if combined with modalities designed to reactive p53, and more broadly, TRIM8 could be considered a new target for therapeutic intervention in cancers where p53 is wild type and its pathway is defective. The gene discussed is TP53; the disease is neoplasm.